A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)

被引:10
|
作者
Liu, Xuechao [1 ,2 ,3 ]
Qiu, Haibo [1 ,2 ,3 ]
Wu, Zhiming [1 ,2 ,4 ]
Zhang, Peng [5 ]
Feng, Xingyu [6 ]
Chen, Tao [7 ]
Li, Yong [6 ]
Tao, Kaixiong [5 ]
Li, Guoxin [7 ]
Sun, Xiaowei [1 ,2 ,3 ]
Zhou, Zhiwei [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 East Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Dept Urol, Guangzhou, Guangdong, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Hubei, Peoples R China
[6] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[7] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
基金
美国国家科学基金会;
关键词
Gastrointestinal stromal tumor; Pathological prognostic score; Ki-67 labeling index; Mitotic index; Prognosis; ADJUVANT IMATINIB MESYLATE; KI-67; THERAPY; KIT; MANAGEMENT; MUTATIONS; DIAGNOSIS; SURVIVAL; IMPACT; TRIAL;
D O I
10.1007/s11605-018-3799-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients. Methods We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015. Results Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index >= 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309-5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05). Conclusion The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.
引用
收藏
页码:2150 / 2157
页数:8
相关论文
共 50 条
  • [31] Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts
    Lin, Yao
    Wang, Ming
    Jia, Jie
    Wan, Wenze
    Wang, Tao
    Yang, Wenchang
    Li, Chengguo
    Chen, Xin
    Cao, Hui
    Zhang, Peng
    Tao, Kaixiong
    EBIOMEDICINE, 2020, 60
  • [32] The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice
    Rutkowski, Piotr
    Zietek, Marcin
    Cybulska-Stopa, Zena
    Streb, Joanna
    Gluszek, Stanislaw
    Jankowski, Michal
    Lopacka-Szatan, Karolina
    Las-Jankowska, Manuela
    Hudziec, Piotr
    Klimczak, Anna
    Olesinski, Tomasz
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Bylina, Elzbieta
    Osuch, Czeslaw
    EJSO, 2021, 47 (05): : 1191 - 1195
  • [33] Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
    Toshirou Nishida
    Yoshiharu Sakai
    Masakazu Takagi
    Masato Ozaka
    Yuko Kitagawa
    Yukinori Kurokawa
    Toru Masuzawa
    Yoichi Naito
    Tatsuo Kagimura
    Seiichi Hirota
    Gastric Cancer, 2020, 23 : 118 - 125
  • [34] Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world
    Nishida, Toshirou
    Sakai, Yoshiharu
    Takagi, Masakazu
    Ozaka, Masato
    Kitagawa, Yuko
    Kurokawa, Yukinori
    Masuzawa, Toru
    Naito, Yoichi
    Kagimura, Tatsuo
    Hirota, Seiichi
    GASTRIC CANCER, 2020, 23 (01) : 118 - 125
  • [35] Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
    Li, J.
    Gong, J. F.
    Wu, A. W.
    Shen, L.
    EJSO, 2011, 37 (04): : 319 - 324
  • [36] Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
    Najjar-Debbiny, Ronza
    Gronich, Naomi
    Weber, Gabriel
    Khoury, Johad
    Amar, Maisam
    Stein, Nili
    Goldstein, Lee Hilary
    Saliba, Walid
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : 453 - 460
  • [37] Narrower clinical margin in high or very high-risk squamous cell carcinoma: a retrospective, multicenter study of 1,000 patients
    Baba, Natsuki
    Kato, Hiroshi
    Nakamura, Motoki
    Matsushita, Shigeto
    Aoki, Megumi
    Fujimoto, Noriki
    Kato, Takeshi
    Iino, Shiro
    Saito, Shintaro
    Yasuda, Masahito
    Asai, Jun
    Ishikawa, Masashi
    Yatsushiro, Hiroshi
    Kawahara, Yu
    Matsuya, Taisuke
    Araki, Ryuichiro
    Teramoto, Yukiko
    Hasegawa, Minoru
    Tokunaga, Takahiro
    Nakamura, Yasuhiro
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (08): : 1088 - 1099
  • [38] Patients with Polyvascular Disease: A Very High-risk Group
    Manolis, Antonis A. A.
    Manolis, Theodora A. A.
    Manolis, Antonis S. S.
    CURRENT VASCULAR PHARMACOLOGY, 2022, 20 (06) : 475 - 490
  • [39] Prognostic implications of biopsy with tumor transection for patients with high-risk primary melanoma
    von Schuckmann, Lena A.
    Khosrotehrani, Kiarash
    Hughes, Maria Celia B.
    van der Pols, Jolieke C.
    Malt, Maryrose
    Smithers, B. Mark
    Green, Adele C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : 1521 - 1524
  • [40] Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
    Dave SB Hoon
    Nature Clinical Practice Oncology, 2004, 1 : 74 - 75